CareDx, Inc. (NASDAQ:CDNA) Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC increased its holdings in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 65.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,989 shares of the company's stock after buying an additional 56,724 shares during the quarter. Calamos Advisors LLC owned about 0.26% of CareDx worth $2,556,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Sterling Capital Management LLC increased its holdings in shares of CareDx by 771.2% in the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares during the last quarter. Tower Research Capital LLC TRC raised its position in CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock valued at $84,000 after buying an additional 3,322 shares during the period. State of Wyoming acquired a new position in CareDx during the fourth quarter valued at $91,000. IQ EQ FUND MANAGEMENT IRELAND Ltd increased its position in CareDx by 41.5% in the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after purchasing an additional 2,742 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of CareDx during the 4th quarter worth about $208,000.

Insider Buying and Selling at CareDx

In other news, Director William A. Hagstrom sold 19,391 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the sale, the director directly owned 53,979 shares of the company's stock, valued at approximately $1,074,182.10. The trade was a 26.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hannah Valantine sold 10,570 shares of the company's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $19.16, for a total transaction of $202,521.20. Following the completion of the transaction, the director owned 38,994 shares of the company's stock, valued at approximately $747,125.04. The trade was a 21.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 129,078 shares of company stock worth $2,234,115 over the last ninety days. 4.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on CDNA. Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Stephens reaffirmed an "overweight" rating and set a $40.00 price target on shares of CareDx in a report on Monday, May 5th. HC Wainwright reissued a "neutral" rating and issued a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. Finally, The Goldman Sachs Group reduced their price target on CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, CareDx currently has a consensus rating of "Moderate Buy" and a consensus price target of $30.33.

CareDx Stock Performance

Shares of CDNA traded up $0.98 on Wednesday, hitting $20.23. 810,869 shares of the stock traded hands, compared to its average volume of 919,681. CareDx, Inc. has a one year low of $14.09 and a one year high of $34.84. The company has a market capitalization of $1.13 billion, a PE ratio of 17.59 and a beta of 2.19. The business has a 50 day simple moving average of $17.81 and a 200 day simple moving average of $19.71.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analysts' expectations of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.03) EPS. On average, equities analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.